The surface antigen (HBsAg) and the e-antigen (HBeAg) in Somalian patients with acute viral hepatitis

Nuti, M.; Harare, Osman; Thamer, G

doi:10.1016/0035-9203(79)90207-4

Cited by 6 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results showed that the proportion of leprosy and tuberculoid patients presenting with HBsAg was 24.4% (54/222) and 11.5% (26/222), respectively, but the overall prevalence of HBsAg-positive patients in this article was 36% (80/222)[ 24 ]. Another study published in this year revealed that among patients with acute viral hepatitis who were tested for the presence of HBsAg and the e-antigen and its corresponding antibodies, HBsAg was found in 60% of patients with hepatitis and 34% of controls, and the overall prevalence of HBsAg-positive patients was 48% (49/102)[ 25 ]. Nuti M and his colleagues also found that 14% (22/157) of patients were HBsAg-positive for the overall prevalence of their study, but in patients with bladder schistosomiasis and in controls, the prevalence was 19.4% (13/67) and 10% (9/90), respectively[ 26 ].…”

Section: Resultsmentioning

confidence: 99%

Epidemiology of viral hepatitis in Somalia: Systematic review and meta-analysis study

Hassan-Kadle¹,

Osman²,

Ogurtsov³

2018

WJG

View full text Add to dashboard Cite

AIMTo provide a clear understanding of viral hepatitis epidemiology and their clinical burdens in Somalia.METHODSA systematic review and meta-analysis was conducted as Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A comprehensive literature search of published studies on viral hepatitis was performed from 1977-2016 in PubMed, Google Scholar, Science Direct, World Health Organization African Index Medicus and the Africa Journals Online databases, as well as on the Ministry of Health website. We also captured unpublished articles that were not available on online systems.RESULTSTwenty-nine studies from Somalia and Somali immigrants (United Kingdom, United States, Italy, Libya) with a combined sample size for each type of viral hepatitis [hepatitis A virus (HAV): 1564, hepatitis B virus (HBV): 8756, hepatitis C virus (HCV): 6257, hepatitis D virus (HDV): 375 and hepatitis E virus (HEV): 278] were analyzed. The overall pooled prevalence rate of HAV was 90.2% (95%CI: 77.8% to 96%). The HAV prevalence among different age groups was as follows: < 1 year old, 61.54% (95%CI: 40.14% to 79.24%); 1-10 years old, 91.91% (95%CI: 87.76% to 94.73%); 11-19 years old, 96.31% (95%CI: 92.84% to 98.14%); 20-39 years old, 91.3% (95%CI: 83.07% to 95.73%); and > 40 years old, 86.96% (95%CI: 75.68% to 93.47%). The overall pooled prevalence of HBV was 18.9% (95%CI: 14% to 29%). The overall pooled prevalence among subgroups of HBV was 20.5% (95%CI: 5.1% to 55.4%) in pregnant women; 5.7% (95%CI: 2.7% to 11.5%) in children; 39.2% (95%CI: 33.4% to 45.4%) in patients with chronic liver disease, including hepatocellular carcinoma (HCC); 7.7% (95%CI: 4.2% to 13.6%), 12.4% (95%CI: 6.3% to 23.0%) and 11.8% (95%CI: 5.3% to 24.5%) in age groups < 20 years old, 20-39 years old and > 40 years old, respectively. The HBV prevalence among risk groups was 20% (95%CI: 7.19% to 44.64%) in female prostitutes, 21.28% (95%CI: 7.15% to 48.69%) in hospitalized adults, 5.56% (95%CI: 0.99% to 25.62%) in hospitalized children, 60% (95%CI: 31.66% to 82.92%) in patients with acute hepatitis, 33.55% (95%CI: 14.44% to 60.16%) in patients with ancylostomiasis, 12.34% (95%CI: 7.24% to 20.26%) in patients with leprosy and 20.19% (95%CI: 11.28% to 33.49%) in schistosomiasis patients. The overall pooled prevalence of HCV was estimated as 4.84% (95%CI: 3.02% to 7.67%). The prevalence rates among blood donors, risk groups, children and patients chronic liver disease (including HCC) was 0.87% (95%CI: 0.33% to 2.30%), 2.43% (95%CI: 1.21% to 4.8%), 1.37% (95%CI: 0.76% to 2.46%) and 29.82% (95%CI: 15.84% to 48.98%), respectively. The prevalence among genotypes of HCV was 21.9% (95%CI: 15.36% to 30.23%) in genotype 1, 0.87% (95%CI: 0.12% to 5.9%) in genotype 2, 25.21% (95%CI: 18.23% to 33.77%) in genotype 3, 46.24% (95%CI: 37.48% to 55.25%) in genotype 4, 2.52% (95%CI: 0.82% to 7.53%) in genotype 5, and 1.19% (95%CI: 0.07% to 16.38%) in genotype 6. The overall pooled prevalence of HDV was 28.99% (95%CI: 16.38% to 45.96%). The HDV prevalence rate am...

show abstract

Section: Resultsmentioning

confidence: 99%

Epidemiology of viral hepatitis in Somalia: Systematic review and meta-analysis study

Hassan-Kadle¹,

Osman²,

Ogurtsov³

2018

WJG

View full text Add to dashboard Cite

show abstract

“…Αναφορικά μέ τήν οξεία ηπατίτιδα Β, στους δικούς μας αρρώ στους τό αντιγόνο e φαίνεται ότι ήταν θετικό σέ όλους κατά τό προϊκτερικό στάδιο, ένώ τό αντίσωμα άντι-e αναπτύχθηκε σύντομα καί μάλιστα στους περισσότερους άρρωστους (77%) στή 3η έως 7η ήμερα από τήν εμφάνιση τοϋ ίκτερου μέ παράλληλη εξαφάνιση τοϋ αντιγόνου άπό τό αίμα άπό αυτούς, ένώ τό αντιγόνο e εξακολουθούσε καί ήταν θετικό στους υπόλοιπους 23% κατά τό χρονικό αυτό διάστημα. Βέβαια, τά ευρή ματα αυτά έρχονται σέ πλήρη αντίθεση μέ τά αποτελέσματα άλλων σχετι κά παλαιοτέρων εργασιών, στις όποιες είχαν χρησιμοποιηθεί λιγότερο ευαίσθητες μέθοδοι, πού δέν βρήκαν τό αντιγόνο στον όρό 30 , 70 , 53 ή πού τό βρήκαν σέ χαμηλό ποσοστό 40 , Στό ήπάτωμα, καί οί 62 άρρωστοι μας βρέθηκαν νά είναι φορείς τοϋ ενός (e) ή τοϋ άλλου δείκτη (άντι-e) τοϋ άντιγονικοϋ συστήματος e. Ειδικότερα, τό e ανιχνεύθηκε σέ ποσοστό 11% καί τό αντίσωμα άντι-e στό 89%. Καί στην ομάδα αυτή τών ηπατοπαθειών τά δεδομένα της βιβλιογραφίας είναι λίγα καί όχι συγκρίσιμα, λόγω χρησιμοποίησης τεχνι κών χαμηλής ευαισθησίας σέ σχέση μέ τά δικά μας.…”

Section: συζητησηunclassified